Adoptive T-cell Immunotherapy of Cancer Using Chimeric Antigen Receptor-Grafted T Cells

Review

DOI: 10.1007/s00005-010-0074-1

Cite this article as:
Davies, D.M. & Maher, J. Arch. Immunol. Ther. Exp. (2010) 58: 165. doi:10.1007/s00005-010-0074-1

Abstract

Harnessing the power of the immune system to target cancer has long been a goal of tumor immunologists. One avenue under investigation is the modification of T cells to express a chimeric antigen receptor (CAR). Expression of such a receptor enables T-cell specificity to be redirected against a chosen tumor antigen. Substantial research in this field has been carried out, incorporating a wide variety of malignancies and tumor-associated antigens. Ongoing investigations will ensure this area continues to expand at a rapid pace. This review will explain the evolution of CAR technology over the last two decades in addition to detailing the associated benefits and disadvantages. The outcome of recent phase I clinical trials and the impact that these have had upon the direction of future research in this field will also be addressed.

Keywords

Chimeric antigen receptor T-cell Cancer Adoptive transfer Survival 

Abbreviations

CAR

Chimeric antigen receptor

HLA

Human leukocyte antigen

MHC

Major histocompatibility complex

TCR

T-cell receptor

chTCR

Chimeric TCR

scFv

Single-chain antibody fragment

TNP

Trinitrophenol

Treg

Regulatory T-cell

IL

Interleukin

EBV

Epstein–Barr virus

HSV-TK

Herpes simplex virus thymidine kinase

Copyright information

© L. Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland 2010

Authors and Affiliations

  1. 1.King’s College London School of Medicine, Research Oncology SectionDivision of Cancer StudiesLondonUK

Personalised recommendations